Thermo Fisher Scientific Inc. $TMO Holdings Boosted by Simplify Asset Management Inc.

Posted by Stanley Muller on Oct 29th, 2026

Simplify Asset Management Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 4.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,130 shares of the medical research company’s stock after acquiring an additional 1,051 shares during the quarter. Thermo Fisher Scientific comprises about 0.3% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 19th biggest holding. Simplify Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $16,289,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. Corient Private Wealth LP bought a new position in Thermo Fisher Scientific during the second quarter valued at approximately $382,547,000. Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific in the second quarter worth approximately $1,974,561,000. Bank of America Corp DE purchased a new stake in Thermo Fisher Scientific in the second quarter worth approximately $1,952,930,000. Finally, Legal & General Group Plc bought a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $1,122,351,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research reports. CLSA started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 target price for the company. Barclays increased their price target on Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. UBS Group restated a “buy” rating and issued a $800.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, October 22nd. BMO Capital Markets lowered Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday, September 9th. Finally, Wells Fargo & Company cut Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $684.55.

Check Out Our Latest Stock Report on TMO

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $704.41 on Thursday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $260.45 billion, a PE ratio of 37.15, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. The firm’s 50 day moving average price is $651.61 and its 200-day moving average price is $552.09. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $710.84.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. The company had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business posted $5.79 earnings per share. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.23 EPS for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael Shafer sold 25,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,368 shares of company stock valued at $43,896,820 over the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.